This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

Major Finding: Brain metastases that arise from various primary sites characteristically harbor chromosomal instability and an immunosuppressive stromal/immune composition.

1Division of Hematology/Oncology, Department of Medicine, University of Washington, Seattle, Washington. 2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. Search for ...

1Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, ...

1Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain. 2Department of Pharmacology and Public Health, Faculty of Medicine, The ...

The FDA granted accelerated approval to the antibody–drug conjugate (ADC) telisotuzumab vedotin (Emrelis; AbbVie), which targets the receptor tyrosine kinase c-Met, for patients with locally advanced ...

The FDA has approved belzutifan (Welireg; Merck) for patients with locally advanced, inoperable, or metastatic pheochromocytoma or paraganglioma (together known as PPGL), rare neuroendocrine tumors ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

With the recent advancements in anti-tumor immunotherapy, novel treatments have emerged and progressed rapidly. Several strategies are now being employed to enhance the efficacy of natural killer (NK) ...

1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.

1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

1Department of Cellular and Molecular Pharmacology, Cell Design Institute, University of California San Francisco, San Francisco, California.